News

Article

Top 10 Video Interviews of 2024

Author(s):

The PharmTech Group editors present our most popular interviews from 2024.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

The editors of Pharmaceutical Technology® and Pharmaceutical Technology® Europe had the fortunate opportunity to sit down with several subject matter experts in the pharmaceutical and biopharmaceutical industry in 2024, with topics ranging from excipient grade choice to data integrity to cell and gene therapies.

The following are some of our most watched video interviews from 2024:

For more exclusive video interview content, please visit PharmTech.com.

Our Drug Digest series can be found at https://www.pharmtech.com/drug-digest.

Our Ask the Expert video series can be found at https://www.pharmtech.com/topic/ask-the-expert.

You can also find the latest conference coverage at https://www.pharmtech.com/latest-conference.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content